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ABSTRACT 
Problem statement: Leishmaniasis caused by Leishmania sp. is second most dangerous 
tropical disease without any specified therapeutic system available. Trypanothione reductase 
plays a key role in survival of the protozoa which can be used as target for Structure based 
Drug designing. Phytochemicals provides a less toxic and accessible source of 
chemotherapeutic agents. The study deals with discovery of one such agent against the 
targeted protein for further Anti-leishmanial drug discovery. 
Method: An in-silico approach was executed in order topfind out theistructure of the targeted 
protein and prominent lead compound as it potential inhibitor. 
Result: The structure of Trypanothione reductase was obtained and validated. It was found to 
be a compatible model suited for further investigation. The docking studies performed 
provided Curcumin as the potential chemotherapeutic agent giving a high binding energy of -
7.9 kcal/mol. The analogues of curcumin presented higher binding energy than base 
compound. Further ADME/T tests suggested two analogues to be prevalent for further study 
with binding energy of -11.0 kcal/mol and -8.8 kcal/mol. 
Keywords: Leishmaniasis, Leishmania, Trypanothione reductase, Phytochemicals, 
Curcumin, in-silico, Docking, Chemotherapeutic, ADME/T 
 
 
 
 
 
 v 
 
TABLE OF CONTENT 
Acknowledgement  iii 
Abstract iv 
Table of content v-vii 
List of figures viii-ix 
List of Tables x 
Abbreviations xi 
1.  INTRODUCTION 1-4 
        1.1.1 Leishmaniasis 2 
1.2 Leishmaniasis and Trypanothione reductase 3 
1.3 Phytochemicals 3 
1.3.1 Curcumin 3 
1.4 Bioinformatics and Drug discovery 4 
1.5 Objective 4 
2. LITERATURE REVIEW 5-13 
2.1 Leishmaniasis 6 
2.2 Clinical presentation of Visceral Leishmaniasis 6 
2.3 Pathogenesis of Leishmaniasis 7 
2.4 Trypanothione reductase in Leishmania species 8 
2.5 Therapeutic approach 9 
        2.5.1 First Line Drugs: 9 
       2.5.2 Clinical trials 9 
2.6 Phytochemicals 10 
 
 vi 
 
3. MATERIALS AND METHODS 14-25 
3.1 Databases, Softwares and Tools used 15 
      3.1.1 UNIPROT 15 
      3.1.2 MODELLER 9.12 15 
      3.1.3 UCSF CHIMERA 15 
      3.1.4 SAVes  15 
      3.1.5 CASTp 15 
      3.1.6 RCSB PDB 16 
      3.1.7 LIGPLOT+ 16 
      3.1.8 PUBCHEM AND CHEMSPIDER 16 
      3.1.9 OPEN BABEL GUI 16 
      3.1.10 PRODRG 16 
      3.1.11 AUTODOCK 4.2 17-18 
      3.1.12 MEDCHEM DESIGNER 18 
      3.1.13 OSIRIS Property Explorer 19 
3.2 PROTOCOL 20-21 
      3.2.1 Modeling of Enzyme structure 20 
      3.2.2 Inhibition study 21 
      3.2.3 Analogue study 21 
3.3 Methodology 22-25 
      3.3.1 Selection of Enzyme 22 
      3.3.2 Homology modeling of the enzyme 22-23 
      3.3.3 Prediction of Active Site 24 
      3.3.4 Retrieval of phytochemical structures 24 
      3.3.5 Docking 25 
 vii 
 
      3.3.6 Analogue design 25 
      3.3.7 Docking of Analogues 25 
      3.3.8 ADME/T test 25 
      3.3.9 Ligplot analysis 25 
4. RESULTS AND DISCUSSION 26-45 
4.1 Results 27-45 
      4.1.1 Homology Modeling  27 
      4.1.2 Structure Validation 28-31 
      4.1.3 Identification of active site 31 
      4.1.4 Superimposition results 31-33 
      4.1.5 Docking 33-36 
      4.1.6 Design of the Analogues 36-38 
      4.1.7 ADME/T Test 39-41 
      4.1.8 Docked image and Ligplot analysis 42-45 
4.2 Discussion 45 
5. CONCLUSIONiAND FUTURE PROSPECTS 46-47 
5.1 Conclusion 47 
5.2 Future perspective 47 
6. REFERENCES 48-50 
 
 viii 
 
 
LIST OF FIGURES 
Fig 2.1: Lifecycle of Leishmania donovani 7 
Fig.2.2: Action of Trypanothione reductase 8 
Fig.2.3: Structures of some common drugs in clinical trial 10 
Fig 2.4: Chart showing distribution of Phytochemicals in Nature 12 
Fig 3.1: Snap shot showing protein sequence of TPR as obtained from UNIPROTKB 22 
Fig 3.2:Snap shot showing protein submission for energy minimization in NOMAD-
Ref 
23 
Fig 4.1: Structure obtained by homology modeling as viewed in Chimera 27 
Fig 4.2: Ramachandran plot as showing the stability of the predicted model 29 
Fig. 4.3: Graphs showing a. Ramachandraniplot quality b. Peptideibond planarity          
c. Bad non-bondediinteractions d. Ca tetrahedralpdistortion e. Main chainlhydrogen 
bond energy f.  OveralltG-factor 
30 
Fig.4.4: CASTp image showing the pocket 1 and the participating residues as viewed in 
CHIMERA 
31 
Fig 4.5: Superimposition of protein sequence of TPR and GR 32 
Fig 4.6:Showing superimposition of TPR and GR and their interaction with FAD 32 
Fig 4.7:  LIGPLOT analysis of TPR and GR showing the difference in their interacting 
residues 
33 
Fig 4.8: Ligplot analysis of Curcumin and TPR 36 
Fig 4.9: Interaction of Analogue 12 and Enzyme as obtained by Autodock 4.2 observed 
in Chimera 
42 
  
 ix 
 
Fig 4.10:  Residues of the enzyme interacting with the analogue 12 visualized in 
Chimera 
42 
Fig 4.11: Interaction of Analogue 13 and TPR as obtained by Autodock 4.2 visualized 
in Chimera 
43 
Fig 4.12: Residues of TPR interacting with analogue 13 visualized in Chimera 43 
Fig 4.13:  Ligplot analysis of Analogue 12 as viewed in LIGPLOT+ and RASMOL 44 
Fig 4.13: LIgplot analysis of Analogue 13 as viewed in LIGPLOT+ and RASMOL 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
 
LIST OF TABLES 
Table1.1:  Limitations of prevalent drugs 9 
Table 4.1: Top 50 ligands showing high affinity to TPR  33-35 
Table 4.2:  Binding energy of top 13 analogues 37-38 
Table 4.3: ADME/T results for curcumin and 13 analogues as obtained from 
OSIRIS server (red mark shows violation of the parameter) 
39 
Table 4.4:  Rules qualified by the specified analogues 40 
 
 xi 
 
 
ABBREVIATIONS 
TR/TPR Trypanothione reductase 
GR Glutathione reductase 
VL Visceral Leishmaniasis 
NADPH Nicotinamide Adenine Dineucleotide phosphate 
FAD Flavin Adenine Dineucleotide 
Leu Leucine 
Val Valine 
Ala Alanine 
Phe Phenylalanine 
Ile Isoleucine 
Tyr Tyrosine 
His Histidine 
Cys Cystine 
Pro Proline 
Gly Glycine 
Thr Threonine 
Met Methionine 
Arg Arginine 
 
 1 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
 
 
 
 
 
 
 2 
 
1.1  Introduction 
1.1.1 Leishmaniasis 
Trypanosomatids are the cause of severalhfatal forms of tropical human diseaseskincluding 
Leishmaniasis. There are over twentypdifferent species of Leishmania causing the disease. 
Leishmaniasis is the wide variety of pathological manifestations that impact differently on 
health and that differuin their severity depending on its interactionlalong with HIVland other 
medical complications [1]. Several species of flagellated parasite of the order 
Kinetoplastidae, genus Leishmania, are responsiblepfor this group of zoonotic infections of 
men and certain animals which is transmitted fly of the genera Phlebotomus and Lutzomyia 
bite the person. Oncelinoculation into the skin takes place, the parasiteslrapidlyllocate to the 
phagolysosomes of the mononuclearlphagocyte system. Human infection can be caused by 
several species of Leishmania whichmare included in four complexes: (1) tropica (L. tropica, 
L. major, L. minor, and L. aethiopica); (2) mexicana (L. mexicana,iL. amazonensis,iL. 
pifanoi, and L.ovenezuelensis); (3) braziliensis or viannia (L.ibrasiliensis, Li guyanensis, L. 
panamensis, and L. peruviana); and (4) donovani (L.idonovani, L. infantum, L. chagasi, L. 
sinesis, and L. nilotica). The importanticlinical syndromes of Leishmaniasis include:  
 Cutaneous leishmaniasis;  
 Muco-cutaneouslleishmaniasis (also referred to as espundia);  
 Visceralpleishmaniasis (called as VL; kala-azar); and  
 Post-kala-azar dermalcleishmaniasis (PKDL).  
VL is instigated byjthe Leishmaniaidonovani complex — L.idonovani causinglin 
theisubcontinent of Indiakand East Africa and L.iinfantum in Europe, Latin Americaland 
North Africa is a systemicldisease that is lethal if leftluntreated. Every year therepare around 
500,000lnewtcases of VLiand over 50,000 deathsifrom theidisease, making it the second 
most fatal parasitic disease after Malaria [2]. 
Various drugslhave been tested and clinically tried for the particularldisease but no efficient 
result has been found aspthere are always some sideleffects related tolthe treatment. This 
condition makeslit more complex to design a proper druglsystem. The vigorous research is 
going on in variouslplaces but the strain which is the main causativelagent of the VL in India 
is yet under researchedpdue to its incomplete information.  
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1.2  Leishmaniasis and Trypanothione reductase  
Trypanothione reductase, an NADPH-dependent flavoprotein which is found specifically in 
protozoan parasites fromithe genera Trypanosoma andiLeishmania is a associate of the 
disulfide oxidoreductase family of enzymes. The NADPH and the thiol-based redox system 
are connected by this key enzyme. Inhibition studies have revealed the importance of TPR in 
theisurvival of theiparasite. Therefore, it is a rational targettfor the development of newtdrugs 
by coherent inhibitor design [3].  
 
1.3  Phytochemicals 
The medicinal plants possess their property of healing as well as of curing of human diseases 
because of the presence of phytochemical constituents. The termt“phytochemicals” refers to a 
extensiveivariety of compoundstproduced bytplants, but it is generally used to designate 
those compounds that possibly have an impact on human health. Instead of identification of 
about thousandsiof phytochemicals, only a small fraction hasibeen studiediclosely. 
Phytochemicals are primary and secondary compounds [22]. Chlorophyll, proteins and 
common sugars are included in primary constituents and secondary compounds have 
terpenoid, alkaloids and phenolic compounds. Phytochemicals have proven themselves to be 
potential chemopreventive and chemotherapeutic agents [25].  
1.3.1 Curcumin 
Curcumin isione of three curcuminoidsifound in Curcuma longa (turmeric), the natural 
phenoliis responsible fortthe yellow color oftturmeric. Curcuminiis a proven agent, 
responsible for most the biological functions of C.longa. The effect of curcumin is being 
tested through clinical trials in humans on various diseases, including multiple myeloma, 
cancer, myelodysplastic syndromes, psoriasis, arthritis, major depressive disorder and 
Alzheimer's disease [27]. The efficacy of Curcumin and its analogues against Leishmaniasis 
have been tested for further drug designing. The Pharmacological grade Curcumin acts as an 
Anti-inflammation, Non-Steroidal, Antineoplastic, Coloring agent and an Enzyme inhibitor 
[28].  
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1.4  Bioinformatics and Drug discovery 
The multi-step process oftdrug discovery startstwith target and lead discovery, followed by 
leadtoptimization and pre-clinicaltin vitro and in vivotstudies to define if suchtcompounds 
fulfill a numbertof pre-set standards for commencing clinical improvement. Thetadvent of 
advanced genomics,tproteomics and bioinformaticstand proficient technologies as High 
ThroughputiScreening (HTS), virtualiscreening, de novo synthesis, in silicoiADMET test and 
structuretbased drug designing revolutionizes this simple method. 
The advanced computational methods, internet sources and ease of their use form the central 
foundation of Structure-based drug designing. Huge amounts of data are being accessed and 
used efficiently for the purpose of drug discovery by means of high-performanceicomputing 
analysis, dataimanagement software andiinternet. The computational techniques increase the 
chance of success in drug discovery and in the design of desirable lead compounds. 
Computation plays a major role in drug designing and discovery at the following 3 stages: 
 Virtual screening and de-novo designing 
 ADME/T prediction 
 Methods for studying protein-ligand binding 
1.5 Objective 
 To identify appropriate target protein for drug discovery against Leishmaniasis. 
 To predict and validate the structure of the enzyme Trypanothione Reductase.  
 To compare the structure with its human analogue (glutathione reductase) to suggest 
its specific action. 
 To find out potential lead compound (phytochemical) for inhibition of the target 
enzyme, Trypanothione reductase. 
 To design novel Phytochemical (Curcumin) analogues as Trypanothione inhibitors. 
 To analyze inhibition action of the analogues through protein ligand interaction using 
AUTODOCK. 
 To perform ADME/T test on the analogues. 
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LITERATURE REVIEW 
2.1 Leishmaniasis 
A group of diseases ranging from self-curing lesions to gross disfigurations and potentially 
deadly visceral disease, by the name Leishmaniasis, are caused by protozoan parasites that 
are transferred by sandflies [1]. The Leishmania genus parasites present enormous differences 
in disease tropism, due to their diverse biological, clinical, and epidemiological nature. 
Leishmania major and other species cause the mildest form of cutaneous leishmaniasis; 
largely limited to lesions around the area of a sandfly bite—though a diffuse form can also 
occur. The destruction of nasopharyngeal tissue by parasites L. braziliensis causes disfiguring 
muco-cutaneous leishmaniasis. Visceral leishmaniasis is causediby the parasitesiof L. 
donovani speciesicomplex that can spread to internal organs and cause death [2,3]. 
 
2.2 Clinical presentation of Visceral Leishmaniasis 
The general infection of liver, spleen and bone marrow results in VL which can affect both 
new and old world species [3]. The characterizing symptoms caused by prolonged infection 
constitute the pentad ofufever, weightiloss, hepatosplenomegaly, pancytopenia,iand 
hypergammaglobulinemia.iPatientsimay suffer with nightisweats, weakness, andianorexia. 
Characteristic skin hyperpigmentation is caused by melanocyte stimulation and xerosis [4]. 
After infection the incubation period varies depending onithe age and immuneistatus ofithe 
patient and the species of Leishmania. Non-treatment leads to frequent death from 
immunosuppression and secondary infections [5].  
The symptoms of VL are generic in various endemic areas, except some specific 
characteristic cases like enlarged lymph nodes, frequent in Sudanese VL patients, rarely 
found in VL patients in India. Hyper-pigmentation, an uncommon symptom and a plausible 
reason for the name ‘kala-azar’, has onlytbeen observe in VLipatients from thetIndian sub-
continent, was aofeature of prolongedpillness in an erapwhen nominal treatmentowas 
notjavailable [3,6]. Clinical image at the initiation of diagnosis is hindered in VL due to 
symptomsland marks of bacterialico-infections such asipneumonia, diarrhoeaior tuberculosis, 
which often tend to continue for severaliweeks before patients eitheriseek medical care or die 
frompbacterial co-infections, massiveibleeding or severeianaemia [4]. 
 
 
 7 
 
2.3 Pathogenesis of Leishmaniasis 
The two distinct forms of the lifecycle of L. donovani: 
 Promastigote flagellar in the gut ofithe arthropod vectortand  
 Amastigoteoform,iwhich grows intracellularlyiin the mammalianihost [4].  
The disease transmission occurs only by female phlebotomine sandflies, bytinoculation of the 
promastigoteiform intotthe skin. The internalization of the parasites takes place byidendritic 
cells andimacrophages in the dermisiand it is transformed in amastigotes after losing their 
flagella [11]. They form a complex parasite–host interaction in phagolysosomes for their 
multiplication and survival. Reticulo-endothelial system is compromised due to infection of 
other monocytes and macrophages by the dissemination of the parasite through thetlymphatic 
and vasculartsystems resulting iniinfiltration of the bonetmarrow, hepatosplenomegalytand 
sometimestenlarged lymph nodesp(lymphadenopathy) [5, 9].  
 
 
Fig 2.1: Lifecycle of Leishmania donovani [4] 
 
The infection is controlled by the host specific cell-mediated immune (CMI) response. The 
incapability to control L.donovani infection in the VL prone subjects is related with a 
profoundiT-cell unresponsivenessito its antigens and theiproduction ofiinterleukin 10 [17]. 
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2.4 Trypanothione reductase in Leishmania species 
Development of airational approach to theydesign of newtanti-leishmanials released new 
aspectstin leishmania biochemistrytwhich can be explored. A targeted study isithe 
intracellulartdithiol trypanothione [N
1
,N
8
-bis(glutathionyl)spermidine], exclusive toiall 
kinetoplastidatincluding the parasitestresponsible for Chagas’tdisease (Trypanosoma cruzi) 
and Africanitrypanosomiasis (Trypanosoma brucei spp) and the Leishmania spp [21]. Many 
of theianti-oxidant andtother protectivetfunctions ascribed to glutathionetin other organisms 
includingtmammals are executed by Trypanothione T(SH)2, being a major low-molecular-
masstthiol in thesetparasites. In comparison to GSH, T(SH)2 is a much more efficient 
protector against 
•
NO [6,18]. This reliability of Trypanosomatids on T (SH)2 assists them in 
controlling the redox states on exposure to higher 
•
NO levels in the mammalian host. The 
intracellular level of dihydro trypanothione is maintained by trypanothione reductase (TR) 
and subsequently results in the maintenance of the reducing environment [19]. TR down-
regulation studies show its vitality in the parasite's physiology, in the case of Leishmania. 
Also, TRtdown-regulation weakens infectivitytand survivaltinicytokine-stimulated 
macrophages.tTRs are structurally analogous to GRsiand are members oftthe family of 
NADPH-dependenttflavoprotein oxidoreductase. Thetreduction of T(S)2  [7,10] by TR is 
aided by the use of NADPH as an e
-
 donor. TRs possess distinct substrate specifities in 
comparison to human GR. Hence; TR makes an optimum target foriantiparasitic drugs. 
Consequently, humongous amounts of efforts are being invested in the pursuit for selective 
TRiinhibitors in researching for the treatment of trypanosomiasis and leishmaniasis [15]. 
 
 
Fig 2.2 Action of Trypanothione reductase [6] 
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2.5 Therapeutic approach 
The inhibition of disease at initial stage suggests the possibility of generation of vaccine 
against Leishmania but it has not yet been possible. There are limited drugs available for the 
treatment of VL and have shown various shortcomings [8]. Pentavalent antimony instead of 
being used as effective drug has become outdated because of development of resistance in 
some parts of the World. The drugs which are or have been used against Leishmania have 
shown negative outcomes at some point [1, 9]. The list of drugs is given below: 
2.5.1 First Line Drugs: 
 Sodiumtstibogluconate (Pentostam,tSSG); meglumineiantimoniate (Glucantime)  
 AmphotericintB (Fungizone) 
 LiposomaltamphotericinfBt(AmBisome) 
 Pentamidine 
2.5.2 Clinical trials: 
 Miltefosine (oral,tPhase IV; registered in India ) [16] 
 Paromomycint(Phase III) 
 Sitamaqinet(oral, Phase II) 
 Otheriamphotericin Biformulations [7, 12, 13] 
 
 
S.no Drug Limitations 
1 Pentavalent antimonials Variable efficacy, Resistance development 
2 Amphotericin B Adverse effects, High toxicity 
3 Pentamidine Low efficacy, High toxicity 
4 Miltefosine Renal toxicity, Teratogenicity 
5 Paromomycin Ototoxicity, Liver problems 
 
Table 2.1 Limitations of prevalent drugs 
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Fig 2.3: Structures of some common drugs in clinical trial [2] 
 
 
2.6 Phytochemicals 
The word ‘phyto-’ is Greekifor plant. Bioactive, non-nutrientiplant compounds obtainedtfrom 
in fruits,tvegetables, grains, and otheryplant foods are termed as Phytochemicals. They, when 
altered to be edible, reduce the threat of major chronic diseases [20]. Their presence confers 
with resistance against pathogens, be it bacteria, fungi or protozoa. These bioactive 
components show remarkable antimicrobial effects in vitro leading to anti-pathogenicity of 
plants. In locales where commercial drugs are unavailable and/or are too expensive, and an 
abundance of medicinal herbs is evident, like Africa treatment of infections is often resorted 
with the local and indigenous plants [22]. Infectious pathologies are being treated by 
employment of plantiparts and their componentstlike roots, leaves, stem barks,tflowers or 
combinations,tessential oils inothe urinary tract, respiratory system, biliary and gastro-
intestinal systems along with the skin. A variety of phytochemicals, with antibacterial 
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activity, exist in plants. Plant materials are colossal and ubiquitous reservoir of the 
polyphenolic phytochemicals. 
The side effects, generally caused by synthetic chemicals, are almost never observed in the 
plants, being the natural reservoirs of medicinal agents [23]. Herbal medicine is acceptable to 
be the main channel of medication for a large proportion of worldipopulation, primarily inithe 
developing and third-world countriestfor primary healthtcare, owing to bettertcultural 
acceptability and bettertcompatibility with theyhuman metabolism, and fewer side-effects. 
The abuse of syntheticidrugs withtimpurities results in higher frequency of adverse drug 
reactions, motivating the researchers to retrace to natural substances for safer remedies [24]. 
The WHO publishedistandards foriherbal safetyito minimize adulteration andtabuse to avoid 
caused by various vernacular names due to widespread locations of remedial plants [12, 25]. 
The usestof the phytochemical agents inttraditional medicine led to isolation of numerous 
modern drugs from natural sources. Evolution of a generalizedodefense mechanismiagainst 
low levelsiof phytochemicals in human enables consumption of manyidifferent plant species 
containingtvariable levels of natural pesticides (carcinogens)twithout consequent side effects 
or ill health, acts in the favor of phytochemicals,tamong an projected 10,000tsecondary 
productsi(natural pesticides) [30]. 
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Fig 2.4: Chart showing distribution of Phytochemicals in Nature 
 
Synthesis of Phenolics in plants is obtained from phenylalanine, resulting from the actioniof 
phenylalanine ammoniailyase (PAL). Plant phenolics play a vital part in the plant’s defense 
mechanism againstipathogens and herbivore predators, andithus, as a derivative, are used in 
limiting the humanipathogeniciinfections [26].  
Alkaloids, a class of natural, nitrogen-based, organic compounds, have diverse and important 
physiological effects on humans and other animals. Prominent examples include 
morphine, strychnine, quinine, ephedrine, and nicotine [25, 29]. 
Flavonoids, being the most diverse group of phytochemicals may prove to be aniimportant 
phytochemicaltgroup contributing to theoreduced mortality rates observed8in people who 
consume high levelsiof plant-basedifoods [25]. 
 13 
 
A multitude of molecular targets can be targeted with various Phytochemicals such as 
epigallocatechin-3-gallatei(EGCG) from green tea, curcuminifrom turmeric, andiresveratrol 
from rediwine. Definitiveimechanisms of action for phytochemicals are notiavailable despite 
extensive research, owing to these characteristics [30].  
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MATERIALS AND METHODS 
 
3.1 Databases, Softwares and Tools used 
3.1.1 UNIPROT 
UNIPROT (Universal Protein Resource) is a inclusive freely accessible high quality database 
of protein sequences and their functional information. It provides 4 core databases:  
i. UniProtKB- Protein database partially curated by experts 
ii. UniParc- Protein comprehensive and non-redundant database 
iii. UniRef- 3 databases of clustered sets of proteins from UniProtKB and UniParc 
iv. UniMes- Database of Metagenomic and Environmental data 
3.1.2 MODELLER 9.12  
Modeller assists in homology or comparative 3D structure protein modeling. Spatial restraints 
consummation is implemented in protein structure modeling. It takes anialignment of the 
sequenceito be modeled with knownirelated structure andicalculatesia modelicontainingiall 
non-hydrogeniatoms [31, 32]. 
3.1.3 UCSF CHIMERA 
UCSF Chimera is athighly extensible program fortinteractive visualization and analysistof 
molecular structurestand related data, including sequence alignments, docking results, density 
maps, supramolecular assemblies, trajectories,tand conformational ensembles. Hightquality 
imagestand movies can betgenerated. It is a freeware for academic purpose [33]. 
3.1.4 SAVes  
SAVes (Structural Analysis and Verification Server) validates the modeled structure. It 
provides Ramachandram Plot analysis, PROCHECK analysis and ERRAT score. All of these 
parameters verify the structural stability and provides the refinement of the structure [34, 35]. 
3.1.5 CASTp 
CASTp (Computed Atlas of SurfacetTopography of Proteins) istantonline web server for 
predictiontof binding sites and activeisites of proteins and DNAs by determining the 
structural pockets and cavities in the protein [36]. 
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3.1.6 RCSB PDB 
It is a collection of 3D structures of large biomolecules such astproteins and nucleic acids, 
obtainedtby X-ray Crystallography and NMRtspectroscopy. It’s a key resource in the area of 
Structural Biology. 
3.1.7 LIGPLOT+ 
The software used for automatic generation of schematic diagram of protein-protein 
interaction and protein-ligand interaction. 
DIMPLOT: Protein-protein interaction 
LIGPLOT: Protein-ligand interaction [37] 
3.1.8 PUBCHEM AND CHEMSPIDER 
These are the free structural databases of chemical compounds. They provide the structural, 
functional and bioactivity information of the small molecules. 
3.1.9 OPEN BABEL GUI 
Open Babelois a chemical toolboxidesigned to communicate various languagesiof chemical 
data. It's aniopen, collective project which allows anyoneito search,iconvert, analyze, ortstore 
data fromimolecular modeling, biochemistry, solid-stateimaterials, chemistry, or relatediareas 
[38].  
3.1.10 PRODRG 
PRODRG takes a descriptioniof a small moleculeu(as PDB coordinates / MDLiMolfile / 
SYBYL Mol2 file / textudrawing) to generate energy-minimized coordinates various formats. 
This energy minimized molecule leads to better protein-ligand interaction and Docking 
results. 
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3.1.11 AUTODOCK 4.2 
It is a suiteiof automated dockingttools. It provides the prediction of binding of small 
molecules,tsuch as substrates or drugtcandidates to a receptor of known 3Distructure. It 
provides one of the best docking results and is a freeware for academic purpose. The 
procedure of Autodocking includes following steps: 
1.  Preparation of Protein target 
 File -> Read molecule (Opens a file browser, Select target.pdb and click on Open) 
 Edit -> Hydrogen -> Add Polar only 
 Edit -> charges -> Add kollmann charges 
 Edit -> atoms -> Assign AD4 type 
 File -> save-> write pdbqt 
2. Preparation of Ligand File 
 Ligand -> Input Molecule -> Read Molecule (Choose ligand.pdb and Click on Open) 
 Ligand -> torsion tree -> choose root 
 Ligand -> torsion tree -> detect root 
 Ligand -> output -> save as .pdbqt 
3. Preparing the macromolecule file. 
 Grid -> Macromolecule -> Choose Macromolecule 
 Choose target  
 Grid -> Set Map Types -> Choose Ligand -> select Ligand 
 Grid -> Grid Box 
 Opens the Grid Options  
 Adjust the number of points in each dimension to 60. 
 The spacing between grid points can be adjusted & the default value is 0.375 Å 
between grid points. 
 Set the  x  center, y center and z center entries. This will center the grid box on the 
active site. 
 Close this widget by clicking File ➞ Close saving current. 
 Grid -> output -> save as .gpf 
4. Autogrid generation 
 Run -> Run AutoGrid (Opens the Run AutoGrid widget) 
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 Program Pathname: entry specifies the location of the autogrid3 executable. 
 Parameter Filename: entry specifies the gpf file 
 Log Filename: entry specifies the log file. Selecting a gpf creates a possible related 
name for the glg. 
 Launch 
5. Preparing the docking parameter file 
 Docking -> Macromolecule -> Set Rigid Filename 
 Docking -> Set Ligand Parameters -> Choose Ligand Click Select Ligand 
 Docking -> Set Search Parameters -> Genetic Algorithm Parameters 
 Docking -> output -> Lamarckian Genetic Algorithm (LGA) 
 Save as .dpf file 
6. Starting AutoDock 
 Run -> Run AutoDock (Opens the Run AutoDock widget) 
 Program Pathname: entry specifies the location of the autodock4 executable.  
 Parameter Filename: entry specifies the dpf file.  
 Log Filename: entry specifies the log file. Selecting a dpf creates a possible related 
name for the dlg. 
 Launch 
7. Saving results 
 Open .dlg file 
 Search for RMSD 
 Copy the best RMSD calculation in target.pdb 
 Save as result.pdb 
 Observe using UCSF CHIMERA [39, 40] 
3.1.12 MEDCHEM DESIGNER 
It is a tool combining molecule drawing feature with basic ADME predictions. It can be used 
to design new molecules which can be saved in .sdf, .mol or smiles format and can then be 
used for further purpose. 
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3.1.13 OSIRIS Property Explorer 
It is used toidraw chemical structure and calculation of varioustdrug relevanttproperties. It 
provides following properties: 
1. Toxicity Risk assessment: The OSIRIS server searches for potential toxicity risks of 
the valid chemical structure provided on 4 major grounds: Mutagenecity, 
Tumorogenicity, Irritant, Reproductive impairment. Risk alert classify the structure as 
harmful according to the specified risk category. The compounds can be categorized 
as having low risk, mediumirisk and highirisk. 
2. cLogP: LogP is the logarithmiof partition coefficient between n-octanol andtwater log 
of a compound which is a measure of hydrophilicity of compounds. High LogP value 
causes poor absorption or permeation specifying low hydrophilicity. For proper 
absorption of drug logP value must not be greater than 5.0 
3. Solubility: It affects absorption and distribution characteristics of a compound. Low 
solubility leads to bad absorption and should be avoided. LogS value is unit stripped 
logarithm of solubility measure in mol/l. Efficient drugs have the estimated logS 
value greater than -4.0. 
4. Molecular weight: Optimization of drug increases in accordance to the molecular 
weight of the compound but after a limit it tends to decreased bioactivity. Thus, MW 
of a compound has to be kept optimum. It is usually preferred to be lower than 500. 
5. Drug likeness: The equation below sums up the score values present in the molecule 
under investigation and leads to calculation of drug likeness: 
d= Σvi/  
A positive value indicates presence of predominant fragments in commercial drugs. 
6. Drug score: It is the combination of drug likeness, clogP, logS, MW and toxicityirisks 
in one handyivalue to judge compound’s overalltpotential to ualify for a drug. Its 
equation sums up as: 
ds= Π (1/2 + ½ si) . Πti 
ds= drug score 
si= contribution calculated directly from clogP, logS, MW and drug likeness 
ti= contribution taken from 4 toxicity risk types 
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3.2 PROTOCOL 
3.2.1 Modeling of Enzyme structure 
Retrieval of amino acid sequence of Trypanothione reductase from UNIPROT 
 
3D structure of enzyme was predicted using MODELLER 9.12 software 
 
Energy minimization of structure was done using online server NOMAD-Ref 
 
The structure validation was done using online SAVES server 
 
Prediction of Active site was done using CASTp 
 
Retrieval of 3D structure of Glutathione reductase from PDB 
 
Superimposition of both enzymes using CHIMERA 
 
LIGPLOT analysis for enzymes for FAD binding site 
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3.2.2 Inhibition study 
Retrieval of phytochemicals from Pubchem and CHEMSPIDER database 
 
Open Babel GUI was used to convert .sdf and .mol files to .pdb format 
 
Energy minimization was done using PRODRG SERVER 
 
Docking of TPR was done using AUTODOCK 4.2 
 
Specific phytochemical was selected based on Binding affinity 
 
3.2.3 Analogue study 
Analogues of the selected compound were prepared using MEDCHEM DESIGNER 
 
Open Babel was used to convert saved .mol format to .pdb format 
 
Energy minimization was done using Prodrg server 
 
Docking of analogues was done using AUTODOCK 4.2 
 
Osiris server was used to test ADME/T 
 
Retrieval of the residues interacting using LIGPLOT 
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3.3 Methodology 
3.3.1 Selection of Enzyme 
The enzyme was selected on the basis of its functioning in the pathogen. As the enzyme 
Trypanothione reductase plays a significant role in maintaining the Leishmania donovani, it 
was taken as the target. The 3D structure of the trypanothione reductase is not available so 
the amino acid sequence was taken from the UNIPROT database ID P39050 
(http://www.uniprot.org/uniprot/P39050).  
i. UNIPROT webpage was browsed. 
ii. Protein Knowledgebase was searched for Trypanothione reductase in Leishmania 
donovani. 
iii. Accession number P39050 was selected. 
 
 
Fig 3.1: Snap shot showing protein sequence of TPR as obtained from UNIPROTKB 
 
3.3.2 Homology modeling of the enzyme 
The aminoiacid sequence was used as inputifor finding the homologousiprotein sequences 
withi3D structure usingkBLASTp (http://blast.ncbi.nlm.nih.gov/Blast.cgi) programoagainst 
PDB databaseiin NCBI. The aminoiacid sequenceiof trypanothione reductase wastaligned 
with theiidentified homologousiproteins using Clustal X foriunderstanding thetconservation 
of amino acidstthroughout the proteintfamily. The three dimensionaltstructure of 
trypanothione reductase from the cytoplasm of L.donovani was predicted using trypanothione 
reductase from  L.infantum (PDB ID: 2JK6) with Modeller 9.12 software 
(http://www.salilab.org/modeller) usingisequence alignment andistructural coordinatesiof the 
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templatetas input. The initialihundred modelsigenerated for Trypanothione reductase were 
prioritizedion the basis ofiMOLPDF, discrete optimizediprotein energy (DOPE) andtGA341 
score.  
i. Structure related to TPR was searched. 
ii. Template was selected. 
iii. TPR was aligned with the template; here Trypanothione reductase of Leishmania 
infantum. 
iv. Model was built. 
v. Model was evaluated. 
Energy minimization of protein is done in order to release internal constraints which lead to 
developing of a more stable structure. This was done using online NOMAD-Ref server 
(Normal Mode Analysis, Deformation and Refinement). The structure was submitted to the 
server and the minimized structure was obtained. 
The finalimodel obtained withireasonable statisticsp(MOLPDF and DOPE) wasivalidated in 
SAVESiserver (http://nihserver.mbi.ucla.edu/SAVES/). The finalimodel was analyzed1with 
PROCHECKkandoERRATkplotlandmvisuallyoinspectedhwithqUCSFhChimera 
(http://www.cgl.ucsf.edu/chimera/). 
 
 
Fig 3.2: Snap shot showing protein submission for energy minimization in NOMAD-Ref  
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3.3.3 Prediction of Active Site 
The small port of enzyme meant for substrate binding can be predicted using various tools 
available. This provides the pocket for the binding of the substrate and plays a vital role in 
action of the enzyme. The active site prediction was done using CASTp server It uses the 
weighted Delaunay triangulation and the alpha complex for shape measurements. It provides  
i. Identification and measurements of surface accessible pockets. 
ii. Interior inaccessible cavities, for proteins and other molecules.  
iii. Analytical measurement of the area and volume of each pocket and cavity, both in 
solvent accessible surface (SA, Richards' surface) and molecular surface (MS, 
Connolly's surface).  
iv. Measurement of the number of mouth openings, area of the openings and 
circumference of mouth lips, in both SA and MS surfaces for each pocket. 
Retrieval of 3D structure of Glutathione reductase 
The PDB (Protein Data Bank) is the universal store of Structural data of Biological 
macromolecules. In it the structures of macromolecules assessed by X-ray Crystallography 
and NMR are available. Glutathione reductase is human analogue of TPR. Its 3D structure 
was obtained from PDB (http://www.rcsb.org/pdb). In the process: 
i. The mentioned url was searched. 
ii. The query was given in the search. 
iii. Various search options were obtained but the structure id 3GRS was selected. 
This structure was superimposed on the TPR structure to observe the difference between the 
structure and their potential ligand binding sites. 
 
3.3.4 Retrieval of phytochemical structures 
The structures were obtained from Pubchem or CHEMSPIDER which are the databases of 
chemical compounds and micromolecules. The 3D structures downloaded in .sdf or .mol 
format were converted to .pdb format using Open Babel GUI and were observed using 
CHIMERA software. For few ligands the 3D structure was not available. In that case the 2D 
SMILES format was input online in CORINA (http://www.molecular-
networks.com/online_demos/corina_demo) to obtain the 3D structure. The energy 
minimization of the ligands was done using Ligandscout.  
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3.3.5 Docking 
Docking for the study of binding affinity was done using AUTODOCK 4.2 which provided 
the binding affinity of TPR with various phytochemicals. The 3D structure visualization was 
done using UCSF Chimera. Based on these docking values and further specific activity of the 
phytochemical Curcumin was selected for further study. 
 
3.3.6 Analogue design 
MEDCHEM DESIGNER was used to vary the structure 
i. Medchem window was opened. 
ii. Ligand .mol format was retrieved. 
iii. Change in functional groups by addition or deletion was done. 
iv. The file was saved in .mol format. 
v. Open Babel was used to convert .mol to .pdb. 
vi. Energy minimization was done using the PRODRG server. 
 
3.3.7 Docking of Analogues 
Docking of the energy minimized analogues of Curcumin and TPR was again done using 
Autodock 4.2. 
 
3.3.8 ADME/T test 
ADME/T test was done using MOLSOFT (https://molsoft.com/mprop/) and OSIRIS server 
(http://www.organic-chemistry.org/prog/peo/). 
i. Open Babel was used to convert .pdb or .mol or .sdf format to SMILES. 
ii. These smiles were copied in the window provided (in case of Osiris it has to be typed 
or CAS no. of available compound can be typed and the structure can be varied 
accordingly in the window.) 
iii. The ADME/T and drug likeness score was obtained. 
3.3.9 Ligplot analysis 
It was performed using Ligplot+ which is a free ware. 
i. The Ligplot window was opened. 
ii. Protein-ligand complex in .pdb format was selected. 
iii. Ligand was selected for the interaction study and the plot window was opened. 
iv. The plot was saved. 
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4.1 Results 
4.1.1 Homology Modeling  
The sequence analysis of Trypanothione reductase L.donovani showed maximum homology 
with the Trypanothione reductase of L.infantum (PDB ID: 2JK6) which was showing high 
similarity (>85%) with the structure. Thus, this was taken as the template for the modeling of 
the target enzyme. The 3D structure of the Trypanothione reductase enzyme was generated 
using MODELLER tool.  
 
 
 
Fig 4.1: Structure obtained by homology modeling as viewed in Chimera 
 
The protein ribbon is rainbow-colored from blue at the N-terminus to red at the C-terminus 
using CHIMERA. The spiral structures are the α helices and the arrows represent the β 
sheets. The thread in between are coils and turns.  
C N 
FAD binding 
domain 
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4.1.2 Structure Validation 
The quality of the modeled structure was validated by Ramachandran plot using PROCHECK 
and ERRAT plot. Ramachandran Plot is a plot of torsional angles:  ψ (psi) the C-Cα torsional 
angle against φ (phi) the N-Cα torsional angle of the residues (amino acids) in a 
peptide/protein. A Ramachandran Plot specifies the torsional angles in a protein which are 
allowed and thus provides an insight to the conformations of the amino acids and geometry of 
the protein. The PROCHECK analysis showed that 93.1% structure was in most favored 
region, 6% was in additional allowed region, 0.2% in generously allowed region and 0.7% (3 
residues LEU45, VAL287, ALA363) in disallowed region. The overall quality factor of the 
model from ERRAT, a protein structure verification algorithm, was 90.24% which stipulate 
that the structure is having low steric hindrance and is well in the range of good statistics. 
This plays a key role in determining the structural stability of the proteins and its refinement, 
obtained through crystallographic model building.  
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Fig 4.2: Ramachandran plot as showing the stability of the predicted model 
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Fig 4.3: Graphs showing a. Ramachandran plot quality b. Peptide bond planarity c. Bad non-
bonded interactions d. Ca tetrahedral distortion e. Main chain hydrogen bond energy f.  
Overall G-factor 
 
The six graphs show how the structure black square compares with well refined structure at a 
similar resolution. In the above graphs the purple band in each graph represents the results 
from the well-refined structures; the central line is least-squares fit to the mean trend as a 
function of resolution and the width of the band on either side of it correspond to a variation 
 31 
 
of one standard deviation about the mean. As the structure in every case comes inside the 
band this signifies the stability of the structure.  
4.1.3 Identification of active site 
The active site was given as HIS461 in the UNIPROT but for further clarification CASTp 
was used which gave the largest pocket of area 2559.3 and Volume 3950.3. There are various 
residues participating in the pocket.  
 
 
Fig 4.4: CASTp image showing the pocket 1 and the participating residues as viewed in 
CHIMERA 
4.1.4 Superimposition results 
The superimposition of the TPR and GR showed that the binding site of both the enzymes is 
different and one substrate binding with the TPR will not bind with GR. This interaction 
study was necessary to make sure that the drug designed against TPR does not interact with 
GR in humans causing any side effects. This was done through the sequence alignment of the 
protein sequence of GR from humans and TPR from L.donovani and later superimposing 
both the structures to show the difference in the secondary structure. 
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Fig 4.5: Sequence alignment of GR of Humans and TPR of L.donovani 
  
Fig 4.6: Showing superimposition of TPR and GR and their interaction with FAD 
 
TPR 
GR 
FAD 
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The superimposition image clearly showed that the binding site of TPR and GR is different. 
The LIGPLOT analysis of the FAD binding site further showed the varied interacting 
residues. 
 
Fig 4.7: LIGPLOT analysis of TPR and GR showing the difference in their interacting 
residues 
 
4.1.5 Docking 
Various ligands were taken on the basis of their action on the variants of the enzyme in other 
species and the other strains of Leishmania. The 3D structure was obtained from the 
Pubchem and for those the 3D structures were not available online tool CORINA was used 
for generation of the 3D structure. The 3D structures of ligands were docked with the 
modeled 3D structure of the enzyme and their affectivity was seen on the basis of their 
binding energy. Effective results were obtained using the Autodock 4.2 tool which provided 
some ligands which can be taken for further study on drug discovery.  
Top 50 results are shown in the table below: 
 
S.no Ligand 
Phytochemical 
type 
Pubchem/ 
CHEMSPIDER 
ID 
Molecular 
formula 
Molecular 
weight 
(Da) 
H-bond 
donor 
H-bond 
acceptor 
Binding 
energy 
1 Taxifolin Flavononol CID 439533 C15H12O7 304.2518 5 7 -8.1 
2 Tomatine Alkaloid CID 28523 C50H83NO21 1034.188 13 22 -8.0 
 34 
 
3 Curcumin Curcuminoid CID 969516 C21H20O6 368.3799 2 6 -7.9 
4 Biochanin A Isoflavones CID 5280373 C16H12O5 284.26348 2 5 -7.9 
5 Naringin Flavonoid CID 442428 C27H32O14 580.53458 8 14 -8.0 
6 Garcinia Biflavonoid CID 161259 C30H22O12 574.48848 8 12 -7.9 
7 Celastrol Celastroid CID 122724 C29H38O4 450.60962 2 4 -7.9 
8 Morphinan Alkaloid 16735917 C16H21N 227.34460 1 1 -7.6 
9 Quinidine Alkaloid CID 441074 C20H24N2O2 324.41676 1 4 -7.6 
10 Nobiletin Flavonoid CID 72344 C21H22O8 402.3945 0 8 -7.6 
11 ProcyanidinB2 Proanthocyanidin CID 122738 C30H26O12 578.52024 10 12 -7.5 
12 Thermopsine Alkaloid CID 638234 C15H20N2O 244.3321 0 2 -7.4 
13 Piperine Alkaloid 553590 C17H19NO3 285.3377 0 4 -7.4 
14 Hesperetin Bioflavonoid CID 72281 C16H14O6 302.27876 3 6 -7.4 
15 Quinine Alkaloid CID 8549 C20H24N2O2 324.41676 1 4 -7.4 
16 Kaempferol Flavonol CID 5280863 C15H10O6 286.2363 4 6 -7.4 
17 Rhein Anthraquinone CID 10168 C15H8O6 284.22042 3 6 -7.3 
18 Demethylnobiletin Flavonoid CID 358832 C20H20O8 388.368 1 8 -7.3 
19 Rhombinin Flavonoid CID 228640 C15H20N2O 244.3321 0 2 -7.2 
20 Salsoline Alkaloid CID 46695 C11H15NO2 193.2423 2 3 -7.2 
21 Eicosane Alkaloid CID 8222 C20H42 282.54748 0 0 -7.2 
22 Naringenin Flavonoid CID 932 C15H12O5 272.25278 3 5 -7.2 
23 Chrysophanic acid Flavonoid CID 10208 C15H10O4 254.2375 2 4 -7.2 
24 Oxyanthraquinone Flavonoid CID 53433123 C14H8O3 224.21152 0 3 -7.2 
25 Salsolidine Alkaloid CID 10302 C12H17NO2 207.26888 1 3 -7.1 
26 Colchicine Alkaloid CID 6167 C22H25NO6 399.437 1 6 -7.1 
27 Emetin Alkaloid CID 10219 C29H40N2O4 480.6389 1 6 -7.1 
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28 Brazilein Celastroid CID 6453902 C16H12O5 284.26348 3 5 -7.1 
29 Duartin Flavonoid CID 3666064 C18H20O6 332.3478 2 6 -7.1 
30 Emodin Celastroid CID 3220 C15H10O5 270.2369 3 5 -7.1 
31 Epiafzelechin Flavanol CID 443639 C15H14O5 274.26866 4 5 -7.1 
32 Epicatechin Flavonoid CID 72276 C15H14O6 290.26806 5 6 -7.1 
33 Fistucacidin Flavonoid 4476230 C15H14O6 290.268097 5 6 -7.1 
34 Leucopelargonidin Flavonoid CID 3286789 C15H14O6 290.2680 5 6 -7.1 
35 Lupinine Alkaloid CID 91461 C10H19NO 169.26396 1 2 -7.0 
36 Asphyllic acid Flavonoid CID 171568 C15H22O2 234.33398 1 2 -7.0 
37 Coralyne chloride Alkaloid CID 23306 C22H22ClNO4 399.86738 0 5 -7.0 
38 Cosmosin Flavonoid CID 23663965 C16H14N7NaO5S4 535.576029 2 14 -7.0 
39 Quercetin Flavonol CID 5280343 C15H10O7 302.2357 5 7 -7.0 
40 Catechin Flavanol CID 73160 C15H14O6 290.26806 5 6 -7.0 
41 Iridin Flavonoid 4445090 C24H26O13 522.455383 6 13 -6.9 
42 Tangeritin Flavonoid CID 68077 C20H20O7 372.3686 0 7 -6.7 
43 Daidzein Isoflavone CID 5281708 C15H10O4 254.2375 2 4 -6.7 
44 Palmatine chloride Alkaloid CID 73442 C21H22ClNO4 387.8566 0 5 -6.6 
45 Genistin Flavonoid CID 5281377 C21H20O10 432.3775 6 10 -6.6 
46 Heptacosane Alkaloid CID 11636 C27H56 380.73354 0 0 -6.6 
47 Formononetin Flavonoid CID 5280378 C16H12O4 268.26408 1 4 -6.5 
48 Cytisine Alkaloid CID 10235 C11H14N2O 190.24166 1 2 -6.4 
49 Octacosane Alkaloid CID 12408 C28H58 394.76012 0 0 -6.4 
50 Gardenin B Flavonoid CID 96539 C19H18O7 358.34202 1 7 -6.4 
 
Table 4.1: Top 50 ligands showing high affinity to TPR  
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Instead of showing higher binding affinity Taxifolin, Tomatine and Naringin break the 
Lipinski’s rule of 5 which is one of the most prerequisite condition for the selection of any 
compound as chemotherapeutic agent. The next best phytochemical Curcumin is a 
curcuminoid which is obtained from the roots of Curcuma longa. Curcumin clearly shows 
high affinity towards TPR and its binding energy. The Ligplot analysis of Curcumin as 
shown: 
 
Fig 4.8: Ligplot analysis of Curcumin and TPR 
The Ligplot analysis clearly shows the hydrophobic residues involved in the interaction with 
Curcumin are Gly229, Thr374, Leu333, Phe230, Cys57, Lys60, Tyr198, Ala365, Cys364, 
Val362, Cys375, Gly376. The hydrophobic residue Gly376 is involved in the hydrogen 
bonding. Even though curcumin showed higher affinity, designing of novel compounds 
taking curcumin as the base chain can provide better binding affinity and can be synthesized 
to overcome the low drug score and low availability of Curcumin. 
 
4.1.6 Design of the Analogues 
The analogues were designed using MEDCHEM DESIGNER, keeping the compound ligand 
constant and varying the side chains. 25 analogues were designed for the further study. The 
top 13 ligands which showed better binding affinity than the original ligand are shown in the 
table: 
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S.no Structure Molecular formula Binding energy 
1 
 
 
Original 
-7.9 
2 
 
C21H20O6 -8.3 
3 
 
C22H22O6 -8.6 
4 
 
C23H24O6 -8.4 
5 
 
C20H18O6 -8.5 
6 
 
C19H16O6 -8.7 
7 
 
C22H22O6 -8.4 
8 
 
C23H24O6 -8.5 
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9 
 
C26H22O6 -8.9 
10 
 
C26H24O6 -11.1 
11 
 
C26H26O5 -11.0 
12 
 
C22H22O6 -11.0 
13 
 
C21H20O6 -8.8 
14 
 
C21H20O6 -8.7 
Table 4.2 Binding energy of top 13 analogues 
 
Analogue 9,10, 11, 12 and 13 showed highest binding energy, increasing the affinity of the 
ligand to the enzyme manifolds which signified the better protein-ligand interaction which 
plays role in further inhibition of TPR. 
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4.1.7 ADME/T Test 
The ADME/T test of the resultant analogues was done through OSIRIS and MOLSOFT. This 
provided the insight on the drug likeness of the ligands, which is necessary to consider before 
designing of a drug. To use a compound as chemotherapeutic agent it should first clear the 
toxicity test. The table shows druglikeness score of the top 13 analogues. These are the 
analogues which don’t show any mutagenic, tumorogenic, irritant and reproductive effective. 
For instance one of the analogues showed tumorogenic property which reduces its liability as 
chemotherapeutic agent and thus cannot be considered for further purpose.  
 
S.no clogP Solubility MW TPSA Drug 
likeness 
Drug 
Score 
HBA HBD 
1 2.95 -3.62 368 93.06 -2.83 0.41 6 2 
2 3.58 -3.67 368 96.22 1.91 0.69 6 3 
3 3.36 -3.92 382 93.06 -6.44 0.36 6 2 
4 3.76 -4.22 396 93.06 -6.67 0.33 6 2 
5 2.67 -3.31 354 104 -3.27 0.42 6 3 
6 2.4 -2.99 340 115 -3.48 0.44 6 4 
7 3.22 -3.94 382 82.06 -1.99 0.41 6 1 
8 3.5 -4.25 396 71.06 -2.95 0.37 6 0 
9 4.41 -5.9 430 93.06 -4.87 0.23 6 2 
10 4.29 -4.33 432 93.06 0.8 0.5 6 2 
11 5.0 -4.68 418 75.99 0.63 0.42 5 2 
12 3.86 -3.99 382 85.22 3.99 0.68 6 2 
13 3.58 -3.67 368 96.22 2.99 0.72 6 3 
14 3.58 -3.67 368 96.22 4.54 0.74 6 3 
 
Table 4.3: ADME/T results for curcumin and 13 analogues as obtained from OSIRIS server 
(red mark shows violation of the parameter) 
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clogP: compound’s hydrophilicity, must not be greater than 5.0 
solubility: signifies absorption and distribution of drug, must be greater than -4.0 
MW: Molecular Weight, less than 450 
TPSA: The Polar Surface Area Prediction 
Drug likeness: in the range of greater than -1.0 and less than 5 
Drug score: Efficient in the range of 0 to 2 
HBA: Hydrogen Bond Acceptor (not more than10) 
HBD: Hydrogen Bond Donor (not more than 5) 
 
The ADME/T test provided the drug likeness and drug score of the analogues. This sorted out 
the analogues which can be used for further drug discovery. Out of the 5 above analogues 
analogue 12 and 13 qualified as effective chemotherapeutic agent. These analogues not only 
showed better binding affinity but also showed minimum toxicity level and higher drug score. 
The further toxicity of these 2 analogues was done using DruLiTo software which provides 
insight to the qualification of drugs according to various rules for filtering of drug like 
compounds. 
 
S.no Analogue Rules qualified 
1 
 
Lipinski’s rule of 5, Ghose filter, 
Veber filter, Unweighted QED, 
Weighted QED 
2 
 
Lipinski’s rule of 5, Ghose filter, 
Veber filter, Unweighted QED, 
Weighted QED 
 
Table 4.4:Rules qualified by the specified analogues 
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Lipinski’s rule of 5 
 Less than 5 hydrogen bond donors 
 Less than 10 hydrogen bond acceptors 
 Molecular mass less than 500 daltons 
 logP less than 5 
Ghose Filter 
 logP –0.4 ~5.6 
 Molecular mass 160 ~ 480 
 Polar surface area < 140 
 Molar refractivity 40 ~ 130 
 Number of atoms 20 ~ 70 
Veber filter 
 PSA ≤ 140 
 Rotatable bond count ≤ 10 
QED (Quantitative Estimation of Drug-likeness) 
 Drug likeness -1.0 ~ 5.0 
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4.1.8 Docked image and Ligplot analysis 
Docked images show the interaction of the analogues and its binding with the enzyme. The 
docking image was viewed using CHIMERA. Ligplot analysis is done to observe the 
interacting residues between the compound and the enzyme. The Ligplot of the Analogue 12 
and 13 are given below: 
 
 
Fig 4.9: Interaction of Analogue 12 and Enzyme as obtained by Autodock 4.2 observed in 
Chimera 
 
 
Fig 4.10: Residues of the enzyme interacting with the analogue 12 visualized in Chimera 
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Fig 4.11: Interaction of Analogue 13 and TPR as obtained by Autodock 4.2 visualized in 
Chimera 
 
 
 
Fig 4.12: Residues of TPR interacting with analogue 13 visualized in Chimera 
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Fig 4.13: Ligplot analysis of Analogue 12 as viewed in LIGPLOT+ and RASMOL 
 
                                
  
Fig 4.14: Ligplot analysis of Analogue 13 as viewed in LIGPLOT+ and RASMOL 
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The docked images as seen in CHIMERA shows the interaction of the ligand with nearby 
residues. Ligand binds to the specified binding site which displays the protein-ligand 
interaction and results in the formation of more stable complex.  
LIGPLOT shows the 2D interaction of the ligand and the hydrophobic residues of the protein. 
The interacting hydrophobic residues for analogue 12 are: Leu88, Cys89, Ile73, Tyr69, 
Leu95, Gly66, Tyr210, Pro90 andMet70. 
The interacting hydrophobic residues for analogue 13 are: Arg74, Ile73, Met70, Cys89, 
Pro90, Leu88, Gly66, Leu95, Tyr210 and it forms hydrogen bond with Asn91. 
 
4.2 Discussion 
3D structure of TPR in L.donovani have been created and validated providing a efficient drug 
target in Anti-Leishmanial Drug discovery. The validated structure showed high structural 
stability. The modeled structure showed high ERRAT score of 90.24% which displays its 
stability. The superimposition of TPR and GR showed the difference in active binding site. 
Over 500 ligands and phytochemicals were searched and the top binding affinity obtained by 
Taxifolin (-8.1 Kcal/mol) but Curcumin (-7.9 Kcal/mol) was taken for further purpose 
because of its various pharmacological purpose. Out of 25 designed analogues 13 analogues 
were taken on account of there binding energy. Top 5 analogues were- Analogue 9, 10 , 11, 
12 and 13 showing higher binding energy as -8.9 kcal/mol, -11.1 kcal/mol, -11.0 kcal/mol, -
11.0 kcal/mol and -8.8 kcal/mol. No analogue showed any toxicity and were quite feasible. 
However, analogue 9, 10 and 11 were having the higher logS value which decreases their 
compatibility as drugs. Clearly analogue 12 and 13 with a drug score of 0.68 and 0.72 were 
the best analogues to be taken for further drug discovery.  
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5.1 Conclusion 
The structure designing of enzymes implies the onset of Structure based Drug designing by 
finding out effective lead compounds which can result in inhibition of the enzyme in the 
protozoan.As the enzyme is specific to the parasite it indicates targeted drug action. 
Leishmaniasis is one of the neglected tropical diseases which imposes quite a threat. Various 
efforts to find out effective drug for its tratement have proved not to be efficient. Thus, if by 
any way an effective ligand can be found for inhibition of the growth of the protozoan it will 
be a breakthrough in researches being carried for the purpose. The ligands which were thus 
found to be effective as inhibitor for the target protein are mainly the phytochemicals. The 
ligand Curcumin give quite decent binding energy result and this can be used for further 
study of drug designing. This study thus enlighten one of the hidden aspect of drug designing 
for Leishmaniasis which is one of the delinquent part right now and thus can facilitate further 
drug designing process. Efficacy of Phytochemicals to be used as drugs is based on their 
broad spectrum of action, easy availability and low toxicity. Phytochemicals are being  used 
efficiently for drug designing. For Leishmaniasis too the phytochemicals can be used for drug 
designing and the risk of present therapeutics can be avoided. 
5.2 Future perspective 
Structure based drug designing and Lead discovery have been used efficiently for drug 
designing. The results obtained by the present work is based on accurate and reliable 
softwares which authenticates their usability. The initial prospect of In silico studies prevent a 
lot of cost and work of in vitro and in vivo experiments. As novel compounds designing has 
been done and it has shown remarkable results,it can be used for further Molecular Dynamics 
Simulation to generate the real time behaviour system. Further the result can be corroborated 
by in-vitro and in-vivo studies which will not only lead to new prospect of drug designing but 
also provide us with effective Anti-leishmanial therapeutics. 
 
 
 
 
 
 
 
 48 
 
REFERENCES: 
1. Lucio H. Freitas-Junior, Eric Chatelain, Helena Andrade Kim, Jair L. Siqueira-Neto; Visceral 
leishmaniasis treatment: What do we have, what do we need and how to deliver it? International 
Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 11–19 
2. Simon L. Croft, Karin Seifert & Vanessa Yardley; Current scenario of drug development for 
leishmaniasis; Indian J Med Res 123, March 2006, pp 399-410 
3. Neeraj Suthar, Vikash Kumar Dubey; In silico approach to counter Leishmania donovani by targeting 
cysteine protease B: Structure modeling and inhibitor docking; Global journal of Biochemistry 
4. François Chappuis, Shyam Sundar, Asrat Hailu, Hashim Ghalib, Suman Rijal, Rosanna W. Peeling, 
Jorge Alvar and Marleen Boelaert; Visceral leishmaniasis: what are the needs for diagnosis, treatment 
and control?; Nature review, Nov.2007, Vol.5 
5. Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol 
Infect Dis 27:305–318 
6. World Health Organization (WHO). Control of Leishmaniases: report of a meeting of the WHO Expert 
Committee. Geneva: WHO; 2010. 
7. Khalil, E. A., Zijlstra, E. E., Kager, P. A. & El Hassan, A. M. Epidemiology and clinical manifestations 
of Leishmania donovani infection in two villages in an endemic area in eastern Sudan. Trop. Med. Int. 
Health 7, 35–44 (2002). 
8. Tim Van Assche, Maartje Deschacht, Raquel A. Inocêncio da Luz, Louis Maes, Paul Cos; Leishmania–
macrophage interactions: Insights into the redox biology; Belgium Free Radical Biology & Medicine 
51 (2011) 337–351 
9. Rittig, M.G. & Bogdan, C. Leishmania–host-cell interaction: complexities and alternative views. 
Parasitol. Today 16, 292–297 (2000). 
10. Bond, C.S., Zhang, Y., Berriman, M., Cunningham, M.L., Fairlamb, A.H., Hunter, A.N. 1999. Crystal 
structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the 
structure based discovery of new natural product inhibitors. Structure 7, 81–89. 
11. Mark L. Cunningham and alan H. Fairlamb; Trypanothione reductase from Leishmania donovani 
Purification, characterisation and inhibition by trivalent antimonials; Eur. J. Biochem. 230,460-468 
(1995). 
12. WHO. The World Health Report [online] <http://www.who.int/whr/2002/en/whr02_en.pdf> (WHO, 
Geneva,Switzerland, 2002). 
13. Singh, S. P., Reddy, D. C., Rai, M. & Sundar, S. Serious underreporting of visceral leishmaniasis 
through passive case reporting in Bihar, India. Trop. Med. Int. Health 11, 899–905 (2006). 
14. Boelaert, M. et al. Visceral leishmaniasis control: a public health perspective. Trans. R. Soc. Trop. 
Med. Hyg. 94, 465–471 (2000). 
15. Zijlstra, E. E., el-Hassan, A. M., Ismael, A. & Ghalib, H. W. Endemic kala-azar in eastern Sudan: a 
longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal 
leishmaniasis. Am. J. Trop. Med. Hyg. 51, 826–836 (1994). 
 49 
 
16. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, et al. Phase 4 trial of miltefosine 
for the treatment of Indian visceral leishmaniasis. The Journal of Infectious Diseases 2007; 196(4):591 
598. 
17. Ghalib, H. W. et al. Interleukin 10 production correlates with pathology in human Leishmania 
donovani infections. J. Clin. Invest. 92, 324–329 (1993). 
18. Santhosh K. VENKATESAN, Prakash SAUDAGAR, Anil K. SHUKLA, Vikash Kumar DUBEY; 
Screening Natural Products Database for Identification of Potential Antileishmanial Chemotherapeutic 
Agents; Interdiscip Sci Comput Life Sci (2011) 3: 217–231 
19. Singh AN, Yadav P, Dubey VK (2013) cDNA Cloning and Molecular Modeling of Procerain B, a 
Novel Cysteine Endopeptidase Isolated from Calotropis procera. PLoS ONE 8(3): e59806. 
doi:10.1371/journal.pone.0059806 
20. Kelly, M. R., Xu, J., Alexander, K. E. and Loo, G., Disparate effects of similar phenolic 
phytochemicals as inhibitors of oxidative damage to cellular DNA. Mutat. Res., 2001, 485, 309–318. 
21. Fairlamb, A. H.; Blackburn, P.; Ulrich, P.; Chait, B. T.; Cerami, A. (1985), Trypanothione: a novel bis 
(glutathionyl) spermidine cofactor for glutathione reductase in trypanosomatids. Science, 227, 1485–
1487 
22. Butler MS (2004) The role of natural product chemistry in drug discovery. J Nat Prod 67:2141–2153 
23. Yogisha S, Raveesha KA (2009) In-vitro antibacterial effect of selected medicinal plant extracts. J Nat 
Prod 2: 64-69. 
24. Butler MS (2005) Natural products to drugs: natural product compounds in clinical trials. Nat Prod Rep 
22:162–195 
25. Koehn FE, Carter GT (2005) The evolving role of natural products drug discovery. Nat Rev 4:206–220 
26. Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 
1981–2002. J Nat Prod 66:1022–1037 
27. Belinda J. Cridge,  Lesley Larsen and Rhonda J. Rosengren (2013) Curcumin and its derivatives in 
breast cancer: Current developments and potential for the treatment of drug-resistant cancers 2052-
6199  
28. Joe, B. and Lokesh, B. R., Role of capsaicin, curcumin and dietary n-3 fatty acids in lowering the 
generation of reactive oxygen species in rat peritoneal macrophages. Biochim. Biophys. Acta, 1994, 
1224, 255–263. 
29. Shukla, Y., Arora, A. and Taneja, P., Antimutagenic potential of curcumin on chromosomal aberrations 
in Wistar rats. Mutat. Res., 2002, 515, 197–202. 
30. Shishodia S. Molecular mechanisms of curcumin action: gene expression. Biofactors. 2013; 39:37-55. 
31. N. Eswar, M. A. Marti-Renom, B. Webb, M. S. Madhusudhan, D. Eramian, M. Shen, U. Pieper, A. 
Sali. Comparative Protein Structure Modeling With MODELLER. Current Protocols in Bioinformatics, 
John Wiley & Sons, Inc., Supplement 15, 5.6.1-5.6.30, 2006. 
32. M.A. Marti-Renom, A. Stuart, A. Fiser, R. Sánchez, F. Melo, A. Sali. Comparative protein structure 
modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29, 291-325, 2000. 
 50 
 
33. UCSF Chimera--a visualization system for exploratory research and analysis. Pettersen EF, Goddard 
TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. J Comput Chem. 2004 
Oct;25(13):1605-12. 
34. Laskoswki RA, MacArthur MW, Moss DS & Thorton JM. (1993). PROCHECK: a program to check 
the stereochemical quality of protein structures. J. Appl. Cryst. 26, 283-291. 
35. Colovos C, Yeates TO. (1993). Verification of protein structures: patterns of nonbonded atomic 
interactions. Protein Sci. 2, 1511-1519 
36. Joe Dundas, Zheng Ouyang, Jeffery Tseng, Andrew Binkowski, Yaron Turpaz, and Jie Liang. 2006. 
CASTp: computed atas of surface topography of proteins with structural and topographical mapping of 
functionally annotated residues. Nucl. Acids Res., 34:W116-W118. 
37. Wallace A C, Laskowski R A, Thornton J M (1996). LIGPLOT: a program to generate schematic 
diagrams of protein-ligand interactions. Protein Eng., 8, 127-134. 
38. J. Cheminf. 2011, 3:33 
39. O. Trott, A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new 
scoring function, efficient optimization and multithreading, Journal of Computational Chemistry 31 
(2010) 455-461. 
40. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. and Olson, A. J. 
(2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. 
Computational Chemistry 2009, 16: 2785-91. 
   
 
 
